EURopean Endeavour for Chimeric Antigen Receptor Therapies

Información del proyecto

EURE-CART

Identificador del acuerdo de subvención: 733297

DOI 10.3030/733297

Proyecto cerrado

Fecha de la firma de la CE 5 Diciembre 2016

Fecha de inicio 1 Enero 2017

Fecha de finalización 30 Junio 2021

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total € 5 903 146,00

Aportación de la UE € 5 903 146,00

Coordinado por

AGC BIOLOGICS SPA
Italy

Resultado final

Websites, patent fillings, videos etc. (7)

Launch of dedicated website
Signing-up of dedicated Twitter and LinkedIn accounts
Preparation of a project logo and flyer
A White Paper on the regulatory issues of CAR-T cells
EU Workshop on the regulatory issues of CAR-T cells
Individualised press releases

Individualised press releases. Released in Month 3 and 27.

Half-day education course at Universities

Publicaciones

Peer reviewed articles (9)

Characterization and Functional Analysis of CD44v6.CAR T Cells Endowed with a New Low-Affinity Nerve Growth Factor Receptor-Based Spacer

Autores: Anna Stornaiuolo, Barbara Valentinis, Camilla Sirini, Cinzia Scavullo, Claudia Asperti, Dan Zhou, Yeny Martinez De La Torre, Stefano Corna, Monica Casucci, Simona Porcellini, Catia Traversari
Publicado en: Human Gene Therapy, Edición 32/13-14, 2021, Página(s) 744-760, ISSN 1043-0342
Editor: Mary Ann Liebert Inc.
DOI: 10.1089/hum.2020.216

New targets and technologies for CAR-T cells

Autores: Fabian Freitag, Marius Maucher, Zeno Riester, Michael Hudecek
Publicado en: Current Opinion in Oncology, Edición 32/5, 2020, Página(s) 510-517, ISSN 1040-8746
Editor: Lippincott Williams & Wilkins Ltd.
DOI: 10.1097/cco.0000000000000653

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML)

Autores: Hardikkumar Jetani, Almudena Navarro-Bailón, Marius Maucher, Silke Frenz, Christina Mathilde Verbruggen, Ana Yeguas, María-Belén Vidriales, Marcos González, Judit Rial Saborido, Sabrina Kraus, Katrin Mestermann, Simone Thomas, Halvard Bonig, Maik Luu, Razieh Monjezi, Dimitrios Mougiakakos, Markus Sauer, Hermann Einsele, Michael Hudecek
Publicado en: Blood, 2021, ISSN 0006-4971
Editor: American Society of Hematology
DOI: 10.1182/blood.2020009192

SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF71 normal lymphocytes

Autores: """Tea Gogishvili, Sophia Danhof, Sabrina Prommersberger, Julian Rydzek, Martin Schreder, Christian Brede, Hermann Einsele, and Michael Hudecek"" "
Publicado en: Blood, Edición """Volume: 130", 2017, Página(s) 2838-2847, ISSN 0006-4971
Editor: American Society of Hematology
DOI: 10.1182/blood-2017-04-

The EURE-CART project as a prototype model for CAR T-cell immunotherapy in Europe

Autores: Franco Locatelli, Concetta Quintarelli
Publicado en: European Journal of Immunology, Edición 48/2, 2018, Página(s) 216-219, ISSN 0014-2980
Editor: John Wiley & Sons Ltd.
DOI: 10.1002/eji.201870029

Il Progetto europeo EURE-CART: l'ISS tra i partner del nuovo approccio terapeutico e personalizzato per sconfiggere le malattie neoplastiche

Autores: """F. Moretti, F. Capone, C. Traversari, M.C. Galli"
Publicado en: Notiziario Istituto Superiore Sanità, Edición 31(11), 2018, Página(s) 3-5, ISSN 1827-6296
Editor: Istituto Superiore Sanità

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

Autores: Xiang Zhou, Leo Rasche, K. Martin Kortüm, Sophia Danhof, Michael Hudecek, Hermann Einsele
Publicado en: Frontiers in Immunology, Edición 11, 2020, ISSN 1664-3224
Editor: International Union of Immunological Societies
DOI: 10.3389/fimmu.2020.620312

What is the future of immunotherapy in multiple myeloma?

Autores: Leo Rasche, Michael Hudecek, Hermann Einsele
Publicado en: Blood, Edición 136/22, 2020, Página(s) 2491-2497, ISSN 0006-4971
Editor: American Society of Hematology
DOI: 10.1182/blood.2019004176

Overcoming key challenges in cancer immunotherapy with engineered T cells

Autores: Silvia Arcangeli, Katrin Mestermann, Justus Weber, Chiara Bonini, Monica Casucci, Michael Hudecek
Publicado en: Current Opinion in Oncology, Edición 32/5, 2020, Página(s) 398-407, ISSN 1040-8746
Editor: Lippincott Williams & Wilkins Ltd.
DOI: 10.1097/cco.0000000000000664

Non-peer reviewed articles (1)

Antibody‐Based CAR T Cells Produced by Lentiviral Transduction

Autores: Sabrina Prommersberger, Michael Hudecek, Thomas Nerreter
Publicado en: Current Protocols in Immunology, Edición 128/1, 2020, ISSN 1934-3671
Editor: Greene Pub. Associates
DOI: 10.1002/cpim.93